# A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

> **NCT06664970** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Peking Union Medical College Hospital** · enrollment: 39 (estimated)

## Conditions studied

- MDS

## Interventions

- **DRUG:** Azacitidine or Ruxolitinib combined with Selinexor

## Key facts

- **NCT ID:** NCT06664970
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-11-06
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06664970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06664970, "A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06664970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*